Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, McGlinchey K, Adjei G, Watkins A, Machiesky L, Chen W, Andrews J, Groves M, Morrow M, Stewart RA, Leinster A, Wilkinson RW, Hammond SA, Luheshi N, Dobson C, Oberst M.
Schofield DJ, et al. Among authors: chen w.
MAbs. 2021 Jan-Dec;13(1):1857100. doi: 10.1080/19420862.2020.1857100.
MAbs. 2021.
PMID: 33397194
Free PMC article.